[Abstract unavailable

Metal halide perovskites of the general formula ABX 3 -where A is a monovalent cation such as caesium, methylammonium or formamidinium; B is divalent lead, tin or germanium; and X is a halide anion-have shown great potential as light harvesters for thin-film photovoltaics [1][2][3][4][5] . Among a large number of compositions investigated, the cubic α-phase of formamidinium lead triiodide (FAPbI 3 ) has emerged as the most promising semiconductor for highly efficient and stable perovskite solar cells [6][7][8][9] , and maximizing the performance of this material in such devices is of vital importance for the perovskite research community. Here we introduce an anion engineering concept that uses the pseudo-halide anion formate (HCOO − ) to suppress anion-vacancy defects that are present at grain boundaries and at the surface of the perovskite films and to augment the crystallinity of the films. The resulting solar cell devices attain a power conversion efficiency of 25.6 per cent (certified 25.2 per cent), have long-term operational stability (450 hours) and show intense electroluminescence with external quantum efficiencies of more than 10 per cent. Our findings provide a direct route to eliminate the most abundant and deleterious lattice defects present in metal halide perovskites, providing a facile access to solution-processable films with improved optoelectronic performance.Perovskite solar cells (PSCs) have attracted much attention since their first demonstration in 2009 [1][2][3][4][5] . The rapid expansion of research into PSCs has been driven by their low-cost solution processing and attractive optoelectronic properties, including a tunable bandgap 6 , high absorption coefficient 10 , low recombination rate 11 and high mobility of charge carriers 12 . Within a decade, the power conversion efficiency (PCE) of single-junction PSCs progressed from 3% to a certified value of 25.5% 13 , the highest value obtained for thin-film photovoltaics. Moreover, through the use of additive and interface engineering strategies, the long-term operational stability of PSCs now exceeds 1,000 hours in full sunlight 14,15 . PSCs therefore show great promise for deployment as the next generation of photovoltaics.Compositional engineering plays a key part in achieving highly efficient and stable PSCs. In particular, mixtures of methylammonium lead triiodide (MAPbI 3 ) with formamidinium lead triiodide (FAPbI 3 ) have been extensively studied 5,7 . Compared to MAPbI 3 , FAPbI 3 is thermally more stable and has a bandgap closer to the Shockley-Queisser limit 6 , rendering FAPbI 3 the most attractive perovskite layer for single-junction PSCs.Unfortunately, thin FAPbI 3 films undergo a phase transition from the black α-phase to a photoinactive yellow δ-phase below a temperature of 150 °C. Previous approaches to overcome this problem have included mixing FAPbI 3 with a combination of methylammonium (MA + ), caesium (Cs + ) and bromide (Br − ) ions; however, this comes at the cost of blue-shifted absorbance and phase segregation under...

Summary Epidemiological studies indicate that overweight and obesity are associated with increased cancer risk. To study how obesity augments cancer risk and development, we focused on hepatocellular carcinoma (HCC), the common form of liver cancer whose occurrence and progression are the most strongly affected by obesity amongst all cancers. We now demonstrate that either dietary or genetic obesity is a potent bona fide liver tumor promoter in mice. Obesity-promoted HCC development was dependent on enhanced production of the tumor promoting cytokines IL-6 and TNF, which cause hepatic inflammation and activation of the oncogenic transcription factor STAT3. The chronic inflammatory response caused by obesity and enhanced production of IL-6 and TNF may also increase the risk of other cancers.

No abstract

In general, mixed cations and anions containing formamidinium (FA), methylammonium (MA), caesium, iodine, and bromine ions are used to stabilize the black α-phase of the FA-based lead triiodide (FAPbI3) in perovskite solar cells. However, additives such as MA, caesium, and bromine widen its bandgap and reduce the thermal stability. We stabilized the α-FAPbI3 phase by doping with methylenediammonium dichloride (MDACl2) and achieved a certified short-circuit current density of between 26.1 and 26.7 milliamperes per square centimeter. With certified power conversion efficiencies (PCEs) of 23.7%, more than 90% of the initial efficiency was maintained after 600 hours of operation with maximum power point tracking under full sunlight illumination in ambient conditions including ultraviolet light. Unencapsulated devices retained more than 90% of their initial PCE even after annealing for 20 hours at 150°C in air and exhibited superior thermal and humidity stability over a control device in which FAPbI3 was stabilized by MAPbBr3.

Activation of microglia by classical inflammatory mediators can convert astrocytes to a neurotoxic A1 phenotype in a variety of neurological diseases1,2. Development of agents that could inhibit the formation of A1 reactive astrocytes could be used to treat these diseases for which there are no disease modifying therapies. Glucagon-like peptide-1 receptor (GLP-1R) agonists have been touted as potential neuroprotective agents for neurologic disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD)3-13. The mechanisms by which GLP-1R agonists are neuroprotective are not known. Here we show that a potent, brain penetrant long acting GLP-1R agonist NLY01 protects against the loss of dopamine neurons and behavioral deficits in the α-synuclein preformed fibril (α-syn PFF) model of sporadic PD14,15. NLY01 also prolongs the life and reduces the behavioral deficits and neuropathological abnormalities in the human A53T α-synuclein (hA53T) transgenic (Tg) model of α-synucleinopathy induced neurodegeneration16. We found that NLY01 is a potent GLP-1R agonist with favorable properties that is neuroprotective via the direct prevention of microglial mediated conversion of astrocytes to an A1 neurotoxic phenotype. In light of NLY01 favorable properties it should be evaluated in the treatment of PD and related neurologic disorders characterized by microglial activation.

Highlights d Gut-to-brain propagation of pathologic a-synuclein via the vagus nerve causes PD d Dopamine neurons degenerate in the pathologic a-synuclein gut-to-brain model of PD d Gut injection of pathologic a-synuclein causes PD-like motor and non-motor symptoms d PD-like pathology and symptoms require endogenous a-synuclein

Sestrins are conserved proteins that accumulate in cells exposed to stress and potentiate adenosine monophosphate-activated protein kinase (AMPK) and inhibit activation of target of rapamycin (TOR). We show that abundance of Drosophila Sestrin (dSesn) is increased upon chronic TOR activation through accumulation of reactive oxygen species (ROS) that cause activation of c-Jun N-terminal kinase (JNK) and transcription factor FoxO (Forkhead box O). Loss of dSesn resulted in age-associated pathologies including triglyceride accumulation, mitochondrial dysfunction, muscle degeneration and cardiac malfunction, which were prevented by pharmacological activation of AMPK or inhibition of TOR. Hence, dSesn appears to be a negative feedback regulator of TOR that integrates metabolic and stress inputs and prevents pathologies caused by chronic TOR activation, that may result from diminished autophagic clearance of damaged mitochondria, protein aggregates, or lipids.TOR (target of rapamycin) is a key protein kinase that regulates cell growth and metabolism to maintain cellular and organismal homeostasis (1-3). Insulin (Ins) and insulin-like growth factors (IGF) are major TOR activators that operate through phosphoinositide 3-kinase (PI3K) and the protein kinase AKT (2). Conversely, adenosine monophosphate activated protein kinase (AMPK), which is activated upon energy depletion, caloric restriction (CR), or genotoxic damage, is a stress-responsive inhibitor of TOR activation (2,4). TOR stimulates cell growth and anabolism by increasing protein and lipid synthesis through p70 S6 kinase (S6K), eukaryotic translation initiation factor 4E-binding protein (4E-BP), and sterol response element binding protein (SREBP) (1-3,5) and by decreasing autophagic † To whom correspondence should be addressed. karinoffice@ucsd.edu. Prolonged TOR signaling induces dSesnPersistent TOR activation in wing discs by a constitutively active form of insulin receptor (InR CA ) resulted in prominent dSesn protein accumulation, not seen in a dSesn-null larvae (Fig. 1, A to C). InR CA also induced accumulation of dSesn RNA (Fig. 1, D to F), indicating that dSesn accumulation is due to increased transcription or mRNA stabilization. As dSesn accumulation was restricted to cells in which TOR was activated, the response is likely to be cell autonomous. dSesn was also induced when TOR was chronically activated by overexpression of the small guanine triphosphatase Rheb (Fig. 1G), or clonal loss of PTEN (phosphatase and tensin homolog) or TSC1 (tuberous sclerosis complex 1) (Fig. 1, H TOR signaling generates ROS to induce dSesnIn mammals, transcription of Sesn genes is increased in cells exposed to oxidative stress (9,11) and we observed ROS accumulation, detected by oxidation of dihydroethidium (DHE), in the same region of the imaginal discs in which InR CA or Rheb were expressed (Fig. 2, A (Fig. 2F).FoxO and p53 are ROS-activated transcription factors that control mammalian Sesn genes (9-12,14). The dSesn locus contains 8 perfect FoxO-response elemen...